Back
 OJRA  Vol.3 No.4 , November 2013
Profile of Secondary Bone Cancer in Brazzaville
Abstract: Objectives: To report an epidemiology study and prognosis for metastatic bone tumor. Methodology: It was a descriptive, transversal study on records of patients hospitalized in Rheumatology and Oncology-Radiotherapy departments of the University Teaching Hospital of Brazzaville, Congo from 1 January 2005 to 31 July 2011 (7 years and 6 months). The diagnosis of bone metastasis was made because of the existence of bone pain, or pathological fracture, or bone swelling and a bone-condensing or mixed or osteolytic radiological image. The anatomo-pathological evidence was made after biopsy of the bone lesion or primary cancer. 3687 patients were hospitalized for active cancer, among them 81 had documented bone metastasis. Results: There were 60 men (74.1%) and 21 women (25.9%) with a sex ratio of 2.85. The average age was 53 years, ranging from 3 to 80 years. 75% of patients were more or equal to 50 years old at the discovery of the bone metastasis. Bone pain was the main mode of discovery (67.9% of cases). However, in 6.2% of cases, it was discovered incidentally. The metastasis was bone condensing in 50.7% of cases, osteolytic in 40.7% and mixed in 8.6%. They were unifocal in 25.9% and multifocal in 74.1% of cases. The Primary cancer most frequently found was that of the prostate in 55.6% of cases, breast in 20.7% and rhabdomyosarcoma in 4.9%. In 6.2% of cases, the primary site of cancer was unknown. The average survival was 25 months. Conclusion: The clinical and radiological presentation remains classic. Cancer of the prostate and breast are the main neoplasia responsible for bone metastasis in our series. The discovery of metastasis remains a major evolutionary step of cancer.
Cite this paper: H. Ntsiba, N. N’soundhat, E. Ndounga and A. Ondzala, "Profile of Secondary Bone Cancer in Brazzaville," Open Journal of Rheumatology and Autoimmune Diseases, Vol. 3 No. 4, 2013, pp. 251-254. doi: 10.4236/ojra.2013.34039.
References

[1]   K. K. Li, E. Sinclair, J. Pope, et al., “A Multidisciplinary Bone Metastases Clinic at Toronto Sunnybrook Regional Cancer Centre. A Review of the Experience from 1999 to 2005,” Journal of Pain Research, Vol. 1, No. 1, 2008, pp. 43-48.

[2]   M. S. Virk and J. R. Lieberman, “Tumor Metastasis to Bone,” Arthritis Research and Therapy, Vol. 9, No. S1, 2007, p. 10.

[3]   R. Bileckot, R. C. Miakoundoba and J. B. Nkoua Mbon, “Two Brazzaville Series of Bone Metastases,” Carcinol Prat Afrique, Vol. 8, No. 1, 2008, pp. 57-60.

[4]   M. Ly, A. Ly, M. Rodrigues, et al., “Cancer in Africa, a New Health Challenge. Examples of Mali and Mali Onco Association,” Bull Cancer, Vol. 97, No. 8, 2010, p. 965.

[5]   C. Gombe-Mbalawa and G. Ibara, “Report Functioning Cancer Registry of Brazzaville from January 1st to December 31st 2010,” Cancer Registry of Brazzaville, 2011.

[6]   L. Belaksir, N. Seknaji, M. Touimy, S. Janani, et al., “Bone Metastases: Experience of Rheumatology CHU Ibn Rushd at Casa,” Revue Du Rhumatisme, Vol. 77, No. S3, 2010, pp. A131-A325.

[7]   N. Seknaji, M. Touimy, L. Belksir, et al., “Contribution of Bone Biopsy in Search of Primary Cancer of Bone Metastases,” Revue Du Rhumatisme, Vol. 77, No. S3, 2010, pp. A131-A325.

[8]   M. Vandecandelaere, R. M. Filipo, B. Cortet, L. Catanzariti, B. Duquesnoy and B. Delcambre, “Bone Metastases Revealing: A Comparative Study in 30-Years Intervals,” Revue Du Rhumatisme, Vol. 71, No. 5, 2004, pp. 390-396. http://dx.doi.org/10.1016/S1169-8330(03)00304-1

[9]   P. Houze, R. Ranaivosoar, A. C. Prost, et al., “Bone Metastases of Prostate Cancer: Contribution of Specific Determination of Bone Alkaline Phosphatase,” Immuno-Analyse & Biologie Specialisee, Vol. 10, 1995, pp. 27-33.

[10]   C. Gombe-Mbalawa, D. Diouf, J. B. Nkoua Mbon, et al., “Arrival of Cancer Patients in Advanced Stages: Attempted Identification of Responsibility,” Bull Cancer, Vol. 100, No. 2, 2013, pp. 167-171.

[11]   K. Kogahashi, H. Satoh, H. Ishihakawa, et al., “Bone Metastasis Revealing Primary Tumor. Comparison of Two Series Separated by 30 Years,” Joint Bone Spine, Vol. 71, No. 3, 2004, pp. 224-229. http://dx.doi.org/10.1016/S1297-319X(03)00123-4

[12]   M. H. Vieillard, “Hypercalcemia of Malignancy,” Reflections Rheumatology, Vol. 115, No. 3, 2009, pp. 14-16.

[13]   D. Secarecia, “The Cancer-Related Hypercalcemia,” Ca- nadian Family Physician, Vol. 56, No. 1, 2010, pp. 90-92.

[14]   H. N. Rakoto-Ratsimba, J. C. Razafinahandry, J. A. B. Razafindrabe, F. R. Raherimandimby and P. Ratokobe, “Paratesticular rhabdomyosarcoma. Case Report,” Medecine Afrique Noire, Vol. 49, No. 2, 2002, pp. 83-86.

[15]   S. Nesa, Y. Lefebvre, J. L. Montfort, F. X. Wese and P. Van Cangh, “Paratesticular Rhabdomyosarcoma a Case Report,” Acta Urologica Belgica, Vol. 62, No. 3, 1994, pp. 37-42.

[16]   J. Nsonde-Malanda, E. Makosso, J. F. Peko and C. Gombe-Mbalawa, “Bone Metastases of Endometrial Adenocarcinoma. A Case Report with Review of the Literature,” Medecine Afrique Noire, Vol. 54, No. 6, 2007, pp. 313-316.

[17]   P. N. Scutellari, G. Addonisio, R. Righi and M. Giganti, “Diagnostic Imaging of Bone Metastasis,” Radiological Medicine, Vol. 100, No. 6, 2000, pp. 429-435.

[18]   D. Vilain, A. Hameg and C. Tainturier, “Update on Bone Scintigraphy in Urological Cancers in Adults,” Advances in Urology, Vol. S7, 2008, pp. 202-207.

[19]   C. Proust, J. Proust and A. Maubon, “Imaging Bone Metastases. Nuclear Medicine,” Functional and Metabolic Imaging, Vol. 30, No. 3, 2006, pp. 149-154.

[20]   L. Belaksir, M. Touimy, S. Janani, et al., “Revealing Bone Metastasis of Prostate Cancer,” Revue Du Rhumatisme, Vol. 77, No. S3, 2010, pp. A131-A325.

 
 
Top